Jeff Bird

Jeff Bird serves as Managing Director at Bluebird Ventures since August 2019 and has been a Limited Partner and Managing Director at Sutter Hill Ventures since June 2002. Currently, Jeff is a Board Member at Stanford Health Care and an investor in multiple companies, including Leyden Labs, Foresight Dx, Kriya Therapeutics, Nutcracker Therapeutics, and Epirium. Jeff also holds investor and board member roles at Procyrion, Inc., and has been involved with GRAIL, Inc. since January 2016. Jeff Bird holds an MD and a Ph.D. in Cancer Biology from Stanford University School of Medicine and a Bachelor of Science from Stanford University.